Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: author's response
Clin Microbiol Infect
.
2023 Jun;29(6):815-816.
doi: 10.1016/j.cmi.2023.03.026.
Epub 2023 Apr 1.
Authors
Jiawen Deng
1
,
Eesha Affan
2
,
Cristian Garcia
3
,
Kiyan Heybati
4
,
Fangwen Zhou
5
Affiliations
1
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: dengj35@mcmaster.ca.
2
Faculty of Science, Carleton University, Ottawa, Ontario, Canada.
3
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
4
Mayo Clinic Alix School of Medicine, Mayo Clinic, Jacksonville, FL, USA.
5
Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
PMID:
37011810
PMCID:
PMC10066581
DOI:
10.1016/j.cmi.2023.03.026
No abstract available
Keywords:
Author's Response; COVID-19; Fluvoxamine; SSRI; Systematic review.
Publication types
Letter
Comment
MeSH terms
COVID-19*
Humans
Selective Serotonin Reuptake Inhibitors* / adverse effects
Substances
Selective Serotonin Reuptake Inhibitors